Advertisement
Editorial Desk| Volume 68, ISSUE 4, P631-634, April 2018

Download started.

Ok

From the Editor’s desk....

April 2018
      There is a clear need to identify molecular mechanisms of non-alcoholic steatohepatitis (NASH) to develop novel targeted therapies. Pyroptosis is a highly inflammatory form of programmed cell death. Gasdermin D (GSDMD)-executed programmed necrosis is involved in inflammation and controls interleukin (IL)-1β release. In this issue of the Journal, Xu et al. studied its role in human and experimental NASH. GSDMD and its pyroptosis-inducing fragment GSDMD-N were upregulated in liver tissues of human NASH and correlated with disease severity. Gsdmd−/− mice with experimental NASH exhibit decreased severity of steatosis and inflammation. GSDMD expression was associated with the secretion of pro-inflammatory cytokines and persistent activation of the NF-κB signaling pathway. Reduced steatosis in Gsdmd−/− mice was due to decreased expression of the lipogenic gene Srebp-1c and upregulated expression of lipolytic genes. This translational study reveals that GSDMD plays a key role as a pyroptosis executor in the pathogenesis of steatohepatitis by controlling cytokine secretion and lipogenesis.
      Figure thumbnail fx1
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect